Please ensure Javascript is enabled for purposes of website accessibility

Is This Underappreciated Cathie Wood Stock a Better Buy Than Tesla Right Now?

By Keith Speights - Mar 19, 2021 at 6:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It definitely could have more upside potential.

Pretty much everybody knows Cathie Wood really likes Tesla (TSLA -6.80%). The ARK Investment Management founder and CEO talks about Tesla regularly. And when the electric-vehicle stock dips, Wood usually buys even more for her high-flying exchange-traded funds.

Many of the other holdings in the ETFs managed by Wood don't receive as much attention. However, she pointed to one of them earlier this month in a CNBC interview, referring to it as one of the "most underappreciated" stocks that she owns.

What is this underappreciated stock -- and could it be an even better buy than Tesla?

Chalkboard drawing of rockets shaped like lightbulbs with dollar signs in them with one colored yellow and larger than the others

Image source: Getty Images.

It's in the genes

Wood singled out medical genetics leader Invitae (NVTA -9.47%) as an especially underappreciated stock. The company states that its mission "is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people."

That's the kind of ambitious goal that excites Cathie Wood. It's not surprising, therefore, that two of the ETFs that she manages have positions in Invitae. The stock is the 11th-largest holding in the ARK Innovation ETF and the 17th-largest holding in the ARK Genomic Revolution ETF.

Invitae offers a wide range of genetic testing. Individuals can determine their risks of passing on genetic conditions to children and the most suitable embryos to help ensure a healthy pregnancy can be identified during in vitro fertilization. Healthcare providers can order genetic diagnostics tests for an extensive and growing list of conditions.

Over the last five years, Invitae's trailing-12-month revenue has skyrocketed over 2,400%. That performance trounces Tesla's revenue growth of around 640% during the same period.

Unlike Tesla, however, Invitae isn't profitable yet. But the genetic testing company has a path to profitability over the next few years, especially with the recent acquisitions of ArcherDX and One Codex expanding Invitae's capabilities.

A massive potential market

In the past, the high costs of genetic testing served as a limiting factor for growth in the market. But technological innovations in gene sequencing have reduced the costs of testing and opened the door to a massive potential market. 

Invitae CEO Sean George told CNBC last week that the scenario for genetic testing is similar to what happened in the computing and networking industry around four decades ago. Lower semiconductor costs back then set the stage for an explosion in the market.

How big could the explosion be in genetic testing? Invitae thinks that its total addressable market tops $150 billion annually. It projects that the genetic testing opportunity in senior adults ages 65 and over alone is around $63 billion. The company estimates that the potential genetic-testing market in adults between the ages of 41 and 65 totals around $60 billion.

Invitae believes that it's at an inflection point in the transformation curve for genetic testing. As the company continues to drive costs lower and expands its menu of tests, it expects testing volumes to increase significantly.

Better than Tesla?

To be sure, Invitae hasn't been as big of a winner as Tesla so far. Over the last five years, the healthcare stock has quintupled in value. During the same period, however, Tesla skyrocketed close to 1,500%.

But could Invitae be a better pick than Tesla over the long run? When asked in a Bloomberg interview in December which stock could fuel the biggest gains for ARK ETFs over the next five years, Wood acknowledged that Tesla is in the running. However, she also stated, "The biggest upside surprises are going to come from the genomics space."

That doesn't mean Invitae is necessarily the genomics stock that will emerge as the major surprise winner of the future. It could be, though.

The company's market cap currently stands at only around $8.5 billion. Invitae could potentially be a 10-bagger if it snags a double-digit share of its addressable market. While Tesla has been remarkably successful, it's a stretch to envision the stock becoming a 10-bagger again.

Invitae just might be a better buy than Tesla right now. Even if it's not, though, there's a really good chance the stock won't remain underappreciated for too much longer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Invitae Stock Quote
Invitae
NVTA
$3.44 (-9.47%) $0.36
Tesla, Inc. Stock Quote
Tesla, Inc.
TSLA
$709.81 (-6.80%) $-51.80
ARK ETF Trust - ARK Innovation ETF Stock Quote
ARK ETF Trust - ARK Innovation ETF
ARKK
$41.17 (-4.43%) $-1.91
ARK ETF Trust - ARK Genomic Revolution ETF Stock Quote
ARK ETF Trust - ARK Genomic Revolution ETF
ARKG
$31.25 (-4.67%) $-1.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.